News

Two Alzheimer’s Organizations to Fund Phase 2 Trial of Amylyx Combo Therapy

The Alzheimer’s Association and Alzheimer’s Drug Discovery Foundation will fund a Phase 2 clinical trial of a combination therapy that Amylyx Pharmaceuticals is developing for Alzheimer’s disease. Amylyx will receive $1.85 million for the trial of AMX0035, which consists of an oral formulation of sodium phenylbutyrate (PB) and tauroursodeoxycholic-acid…

FDA Places CT1812, Potential Disease-Modifying Alzheimer’s Treatment, on Fast Track

The U.S. Food and Drug Administration (FDA) has placed CT1812 on fast track as a potential treatment of patients with Alzheimer’s disease (AD), the investigative therapy’s developer,  Cognition Therapeutics, has announced. CT1812 is a first-in-class, orally administered small molecule designed to inhibit the binding of amyloid beta oligomers to nerve…

Alzheimer’s Nonprofit, Pfizer, Johns Hopkins Partnering on Therapy Development

The Alzheimer’s Drug Discovery Foundation and Pfizer’s Centers for Therapeutic Innovation are  supporting a Johns Hopkins University School of Medicine effort to develop therapies for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. Valina Dawson, a neurology professor who is co-director of neuroregeneration and stem cell programs at Johns Hopkins’ Institute for Cell Engineering, will…